AI assistant
Vivesto — Share Issue/Capital Change 2012
Nov 30, 2012
3124_rns_2012-11-30_f5ddb51d-82fd-4e44-8754-d9a59fc6934d.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
2012-11-30
PRESS RELEASE
Publication of change in the total number of shares and votes in Oasmia
The total number of shares and votes in Oasmia Pharma ceutical AB (publ) amounts to81 772 330 as ofNovember30, 2012. The increase inthe number of shares is attributable to thenw share issuewith preferential rightsfor current shareholderscarried out inOctober/November2012, which comprised24 531 699shares. The share issuewas registered in its entirety with the Swedish CompaniesRegistration Office on November 21, 2012.
A list of the company principal shareholders will be available at www.oasmia.com
This press release contains information which Oasmia is required to provideaccording to Financial Instruments Trading Act (1991:980) and/or the Securities Act (2007:528). The information was published onNovember30, 2012 at 9.50.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops a new generation of drugs within hu man and veterinary oncology. The product development aims to manufacture novel formulations based on well established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therap eutic area. The product development is based on in-house research within nanotechnology and company patents. The company was registered in 1999 and is located in Uppsala, Sweden.
For more information, please contact:Johan Edin, actingHead of Public Relations, Oasmia Pharmaceutical AB. E-mail: [email protected]mPhone: +46 (0) 18 50 54 40.Information is also available atwww.oasmia.com www.nasdaqomxnordic.comwww.boerse-frankfurt.de